Only a few of the more than 3,000 radioisotopes that scientists have synthesized in the laboratory are regularly used in diagnostic or therapeutic medicine. One significant barrier to the development of new medical radioisotopes is the difficulty of gaining access to radionuclides during the early stages of development and research. PRISMAP is a new medical radionuclide program designed to streamline that access for medical research in the European Union and the United Kingdom.
October 1, 2021, 12:00PMNuclear News
December 21, 2020, 10:25AMPress Releases
A PDF version of the letter can be downloaded here.
I write on behalf of the American Nuclear Society (ANS) to recommend the EU’s inclusion of nuclear energy as a sustainable energy source securing Europe’s prosperous future. ANS and the 10,000 nuclear technology professionals it represents are committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit humanity.